UCB【UCB】銘柄情報

リアルタイムのストリーミング引用、アイデア、ライブディスカッションのハブ

プレミアム

通貨

188.50

買値

188.00

売値

193.90

出来高

311,737

188.45 日の範囲 196.30

104.35 52 週間の範囲 198.95

時価総額

36.664B

前日終値

192.05

始値

190.70

時刻

251

188.5

最終取引時間

財務取引量

VWAP

平均取引量 (3 か月)

216,056

発行済株式数

194,506,000

配当利回り

PER

34.43

1 株当たり利益 (EPS)

5.48

歳入

5.61B

純利益

1.07B

セクター

Pharmaceutical Preparations

業界

Chemicals & Allied Products

ウェブサイト

www.ucb.com

本社

Brussels, Brussels-capital Region, Bel

設立

1928

UCB SA is listed in the Pharmaceutical Preparations sector of the ユーロネクスト with ticker UCB. The last closing price for UCB was 192.05 €. Over the last year, UCB shares have traded in a share price range of 104.35 € to 198.95 €.

UCB currently has 194,506,000 shares in issue. The market capitalisation of UCB is 37.35 € billion. UCB has a price to earnings ratio (PE ratio) of 34.43.

Dapirolizumab Pegol Phase 3 Data Presented at the American College of Rheumatology Shows Significant Reduction in Systemic Lupus Erythematosus Disease Activity

Dapirolizumab pegol (DZP) met its primary endpoint, demonstrating statistically and clinically significant...

UCB and Biogen Announce Positive Topline Results From Phase 3 Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus and are Initiating Second Phase 3 Study in 2024

Phase 3 PHOENYCS GO study met the primary endpoint demonstrating clinical improvement in moderate-to-severe...

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	8.35	4.63502636692	180.15	196.85	178.5	416314	190.23852659	DE
4	5.4	2.94920808301	183.1	196.85	176.55	262457	186.54132816	DE
12	7.8	4.31654676259	180.7	198.95	176.55	216056	187.37542128	DE
26	28.05	17.4820816454	160.45	198.95	158.15	216206	179.712272	DE
52	79.65	73.1740927882	108.85	198.95	104.35	241142	152.56792304	DE
156	92.8	96.9696969697	95.7	198.95	65.4	267773	103.06509168	DE
260	104.62	124.72579876	83.88	198.95	60.18	284089	97.6845585	DE

UCB - Frequently Asked Questions (FAQ)

What is the current UCB share price?

The current share price of UCB is 188.50 €

How many UCB shares are in issue?

UCB has 194,506,000 shares in issue

What is the market cap of UCB?

The market capitalisation of UCB is EUR 37.35B

What is the 1 year trading range for UCB share price?

UCB has traded in the range of 104.35 € to 198.95 € during the past year

What is the PE ratio of UCB?

The price to earnings ratio of UCB is 34.43

What is the cash to sales ratio of UCB?

The cash to sales ratio of UCB is 6.53

What is the reporting currency for UCB?

UCB reports financial results in EUR

What is the latest annual turnover for UCB?

The latest annual turnover of UCB is EUR 5.61B

What is the latest annual profit for UCB?

The latest annual profit of UCB is EUR 1.07B

What is the registered address of UCB?

The registered address for UCB is 60, ALLEE DE LA RECHERCHE, BRUSSELS, BRUSSELS-CAPITAL REGION, B-1070

What is the UCB website address?

The website address for UCB is www.ucb.com

Which industry sector does UCB operate in?

UCB operates in the CHEMICALS & ALLIED PRODUCTS sector

銘柄コード	株価	出来高
ALEUPEuroplasma	0.02 € (78.57%)	365.72M
MLAZRThe Azur Selection SA	1.13 € (61.43%)	47.07k
ALCYBCybergun	0.0003 € (50.00%)	4.22B
ALJXRArchos	0.241 € (37.71%)	10.35M
ALDOLDolfines	3.21 € (29.96%)	118.41k
DMSBSDiagnostic Medical Systems	0.0015 € (-81.25%)	14.15k
BNBSTonner Drones	0.002 € (-42.86%)	1.61M
TDBSTonner Drones	0.0038 € (-41.54%)	23.76M
BUIBarbara Bui	3.10 € (-24.39%)	1.05k
MLTROTroc de l Ile	2.50 € (-20.38%)	60
ATOAtos SE	0.0046 € (-6.12%)	5.99B
ALCYBCybergun	0.0003 € (50.00%)	4.22B
ALEUPEuroplasma	0.02 € (78.57%)	365.72M
ALTDTonner Drones	0.027 € (-20.12%)	282.8M
BCPBanco Comercial Portugues SA	0.5538 € (2.44%)	91.6M

銘柄コード

株価

出来高

ATOAtos SE

0.0046 €

(-6.12%)

5.99B

ALCYBCybergun

0.0003 €

(50.00%)

4.22B

ALEUPEuroplasma

0.02 €

(78.57%)

365.72M

ALTDTonner Drones

0.027 €

(-20.12%)

282.8M

BCPBanco Comercial Portugues SA

0.5538 €

(2.44%)

91.6M

市場データ

ニュース

投資ツール

市場

発見

Hot Features

Follow Feed

ライブオプションフロー

モニター

UCB SA (UCB)

リアルタイムのストリーミング引用、アイデア、ライブディスカッションのハブ

主要統計と詳細

UCB SA について

UCB 最新ニュース

Dapirolizumab Pegol Phase 3 Data Presented at the American College of Rheumatology Shows Significant Reduction in Systemic Lupus Erythematosus Disease Activity

UCB and Biogen Announce Positive Topline Results From Phase 3 Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus and are Initiating Second Phase 3 Study in 2024

UCB Convening Notice to the General Meeting of the Shareholders 2024

ClearPoint Neuro and UCB Enter License Agreement for Gene Therapy Drug Delivery

UCB Convocation à L’ Assemblée Générale des Actionnaires 2023

Praxis Precision Medicines and UCB Announce Epilepsy Research Collaboration

UCB SA - CONVOCATION A L’ASSEMBLEE GENERALE DES ACTIONNAIRES 2022

Dapirolizumab Pegol Phase 3 Data Presented at the American College of Rheumatology Shows Significant Reduction in Systemic Lupus Erythematosus Disease Activity

UCB and Biogen Announce Positive Topline Results From Phase 3 Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus and are Initiating Second Phase 3 Study in 2024

UCB Convocation à l'Assemblée Générale des Actionnaires 2024

UCB - Frequently Asked Questions (FAQ)

ムーバー

議論

最近閲覧した銘柄

会社情報

ビジネス

人気

アプリを入手

市場データ

ニュース

投資ツール

市場

発見

Hot Features

Follow Feed

ライブオプションフロー

モニター

UCB SA (UCB) 銘柄情報

UCB SA (UCB)

リアルタイムのストリーミング引用、アイデア、ライブディスカッションのハブ

主要統計と詳細

UCB SA について

UCB 最新ニュース

Dapirolizumab Pegol Phase 3 Data Presented at the American College of Rheumatology Shows Significant Reduction in Systemic Lupus Erythematosus Disease Activity

UCB and Biogen Announce Positive Topline Results From Phase 3 Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus and are Initiating Second Phase 3 Study in 2024

UCB Convening Notice to the General Meeting of the Shareholders 2024

ClearPoint Neuro and UCB Enter License Agreement for Gene Therapy Drug Delivery

UCB Convocation à L’ Assemblée Générale des Actionnaires 2023

Praxis Precision Medicines and UCB Announce Epilepsy Research Collaboration

UCB SA - CONVOCATION A L’ASSEMBLEE GENERALE DES ACTIONNAIRES 2022

Dapirolizumab Pegol Phase 3 Data Presented at the American College of Rheumatology Shows Significant Reduction in Systemic Lupus Erythematosus Disease Activity

UCB and Biogen Announce Positive Topline Results From Phase 3 Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus and are Initiating Second Phase 3 Study in 2024

UCB Convocation à l'Assemblée Générale des Actionnaires 2024

UCB - Frequently Asked Questions (FAQ)

ムーバー

議論

最近閲覧した銘柄

会社情報

ビジネス

人気

アプリを入手

広告を削除する